Aurobindo Pharma Gains as US Unit Receives VAI After FDA Inspection
Aurobindo Pharma shares rose 2% after Aurolife Pharma’s US facility cleared an FDA inspection and received a VAI (Voluntary Action Indicated) classification. The FDA inspected the site from March 24 to April 10, 2025, issued an Establishment Inspection Report, and closed the review without enforcement. Aurobindo said pending inhaler and other product applications from the facility can now move ahead.